A case report demonstrating that follicle maturing drugs may create an adverse uterine environment even when not used for controlled ovarian hyperstimulation.
OBJECTIVE
To evaluate whether follicle maturing drugs used in lower dosages for luteal phase defects rather than controlled ovarian hyperstimulation may have an adverse effect on successful implantation.


METHODS
Unique case report.


RESULTS
A 40-year-old woman who failed to conceive after six years of follicle maturing drugs with or without progesterone supplementation and four years of in vitro fertilization with embryo transfer (92 embryos transferred in 10 cycles) successfully conceived with the first cycle after the exclusive use of vaginal progesterone in the luteal phase.


CONCLUSIONS
This case provides convincing evidence that for some women follicle maturing drugs, even when used in lower dosages, can adversely affect the uterine environment.
Check
J H
JH
The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, USA.
Check
M L
ML
D000328:Adult; D002996:Clomiphene / Q000494:pharmacology*; D004624:Embryo Transfer; D004965:Estrogen Antagonists / Q000494:pharmacology; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology*; D006801:Humans; D008183:Luteal Phase; D010062:Ovulation Induction; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000494:pharmacology; D014599:Uterus / Q000187:drug effects*
D004965:Estrogen Antagonists; D005300:Fertility Agents, Female; D002996:Clomiphene; D011374:Progesterone